ROS‑mediated hypomethylation of PRDX5 promotes STAT3 binding and activates the Nrf2 signaling pathway in NSCLC

Cao,Xiang; Chen,Xin‑Ming; Xiao,Wei‑Zhang; Li,Ben; Zhang,Bo; Wu,Qiong; Xue,Qun

doi:10.3892/ijmm.2020.4819

ROS‑mediated hypomethylation of PRDX5 promotes STAT3 binding and activates the Nrf2 signaling pathway in NSCLC

Authors:
- Xiang Cao
- Xin‑Ming Chen
- Wei‑Zhang Xiao
- Ben Li
- Bo Zhang
- Qiong Wu
- Qun Xue
View Affiliations

Affiliations: Department of Thoracic Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226001, P.R. China, Department of Clinical Medicine, Medical School of Nantong University, Nantong, Jiangsu 226001, P.R. China
Published online on: December 15, 2020 https://doi.org/10.3892/ijmm.2020.4819
Pages: 573-582
Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Deoxyribonucleic acid (DNA) epigenetic modification has been linked to specific sequences of CpG islands and plays roles in the progression of lung cancer. In this study, it was found that peroxiredoxin‑5 (PRDX5) was highly expressed in non‑small cell lung cancer (NSCLC) tissues; however, its specific regulatory mechanisms and functions in NSCLC remain unknown. The present study therefore explored the regulatory mechanism of PRDX5 under conditions of oxidative stress (OS) in NSCLC. The results revealed that 79 of 121 NSCLC patients exhibited demethylation in the PRDX5 promoter region, which was related to the tumor, node and metastasis (TNM) stage (P=0.027). PRDX5 messenger ribonucleic acid (mRNA) expression positively correlated with the demethylation status of the promoter region. The results of bisulfite sequencing polymerase chain reaction (BSP) revealed lower demethylation frequencies in H1299 cells treated with 0 µM H2O2, but maximum demethylation following treatment with 100 µM H2O2. Using chromatin immunoprecipitation (ChIP) and luciferase detection assays, the effective binding of STAT3 to the transcriptional binding sites of the PRDX5 promoter region was confirmed (2 sites confirmed: Site 1, ‑444 to ‑434 bp; and site 4, ‑1,417 to ‑1,407 bp). STAT3 knockdown significantly decreased the protein expression of PRDX5, while the overexpression of STAT3 significantly increased the protein levels of PRDX5. When PRDX5 was overexpressed in lung cancer cells under conditions of OS, the levels of the epithelial‑mesenchymal transition (EMT) biomarkers, E‑cadherin and vimentin, were significantly decreased and increased, respectively. By contrast, PRDX5 knockdown resulted in significantly increased E‑cadherin and decreased vimentin protein expression levels. Ultimately, when PRDX5‑small interfering RNA (siRNA) or pcDNA3.1‑PRDX5 expression vector were constructed and transfected into H1299 cells pre‑treated with 100 µM H2O2, the nuclear factor (erythroid‑derived 2)‑like 2 (Nrf2) signaling pathway was inhibited or activated. All these results suggested that the reactive oxygen species (ROS)‑mediated hypomethylation of PRDX5 enhanced STAT3 binding affinity with the promoter region, and resulted in the promotion of cell migration and invasion, as well as in the activation of the Nrf2 signaling pathway in NSCLC. The demethylation status of the PRDX5 promoter may thus be used as an epigenetic biomarker in NSCLC. STAT3/PRDX5 signaling may also prove to be a potential strategy for the treatment of this type of cancer.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
2	Liu SV and Giaccone G: Lung cancer in 2013: Refining standard practice and admitting uncertainty. Nat Rev Clin Oncol. 11:69–70. 2014. View Article : Google Scholar : PubMed/NCBI
3	Song X, Zhao C, Jiang L, Lin S, Bi J, Wei Q, Yu L, Zhao L and Wei M: High PITX1 expression in lung adenocarcinoma patients is associated with DNA methylation and poor prognosis. Pathol Res Pract. 214:2046–2053. 2018. View Article : Google Scholar : PubMed/NCBI
4	Zhang X, Rong X, Chen Y and Su L: Methylation-mediated loss of SFRP2 enhances invasiveness of non-small cell lung cancer cells. Hum Exp Toxicol. 37:155–162. 2018. View Article : Google Scholar : PubMed/NCBI
5	Chen L, Wang Y, Liu F, Xu L, Peng F, Zhao N, Fu B, Zhu Z, Shi Y, Liu J, et al: A systematic review and meta-analysis: Association between MGMT hypermethylation and the clinicopathological characteristics of non-small-cell lung carcinoma. Sci Rep. 8:14392018. View Article : Google Scholar : PubMed/NCBI
6	Raungrut P, Petjaroen P, Geater SL, Keeratichananont W, Phukaoloun M, Suwiwat S and Thongsuksai P: Methylation of 14-3-3s gene and prognostic significance of 14-3-3s expression in non-small cell lung cancer. Oncol Lett. 14:5257–5264. 2017.PubMed/NCBI
7	Zhou Y, Qiu XP, Li ZH, Zhang S, Rong Y, Yang GH and Fang-Zheng: Clinical significance of aberrant cyclin-dependent kinase-like 2 methylation in hepatocellular carcinoma. Gene. 683:35–40. 2019. View Article : Google Scholar
8	Peters I, Dubrowinskaja N, Hennenlotter J, Antonopoulos WI, Von Klot CAJ, Tezval H, Stenzl A, Kuczyk MA and Serth J: DNA methylation of neural EGFL like 1 (NELL1) is associated with advanced disease and the metastatic state of renal cell cancer patients. Oncol Rep. 40:3861–3868. 2018.PubMed/NCBI
9	Li F, Xue ZY, Yuan Y, Huang SS, Fan YH, Zhu X and Wei L: Upregulation of CXCR4 through promoter demethylation contributes to inflammatory hyperalgesia in rats. CNS Neurosci Ther. 24:947–956. 2018. View Article : Google Scholar : PubMed/NCBI
10	Jiang C, Guo J, Cheng H and Feng YH: Induced expression of endogenous CXCR4 in iPSCs by targeted CpG demethylation enhances cell migration toward the ligand CXCL12. Inflammation. 42:20–34. 2019. View Article : Google Scholar
11	Kang D and Hamasaki N: Mitochondrial oxidative stress and mitochondrial DNA. Clin Chem Lab Med. 41:1281–1288. 2003. View Article : Google Scholar : PubMed/NCBI
12	Nogueira V and Hay N: Molecular pathways: Reactive oxygen species homeostasis in cancer cells and implications for cancer therapy. Clin Cancer Res. 19:4309–4314. 2013. View Article : Google Scholar : PubMed/NCBI
13	Lin S, Li Y, Zamyatnin AA Jr, Werner J and Bazhin AV: Reactive oxygen species and colorectal cancer. J Cell Physiol. 233:5119–5132. 2018. View Article : Google Scholar
14	Knoops B, Goemaere J, Van der Eecken V and Declercq JP: Peroxiredoxin 5: Structure, mechanism, and function of the mammalian atypical 2-Cys peroxiredoxin. Antioxid Redox Signal. 15:817–829. 2011. View Article : Google Scholar
15	Kim B, Park J, Chang KT and Lee DS: Peroxiredoxin 5 prevents amyloid-beta oligomer-induced neuronal cell death by inhibiting ERK-Drp1-mediated mitochondrial fragmentation. Free Radic Biol Med. 90:184–194. 2016. View Article : Google Scholar
16	Kim B, Kim YS, Ahn HM, Lee HJ, Jung MK, Jeong HY, Choi DK, Lee JH, Lee SR, Kim JM and Lee DS: Peroxiredoxin 5 overexpression enhances tumorigenicity and correlates with poor prognosis in gastric cancer. Int J Oncol. 51:298–306. 2017. View Article : Google Scholar : PubMed/NCBI
17	Byun JM, Kim SS, Kim KT, Kang MS, Jeong DH, Lee DS, Jung EJ, Kim YN, Han J, Song IS, et al: Overexpression of peroxiredoxin-3 and -5 is a potential biomarker for prognosis in endometrial cancer. Oncol Lett. 15:5111–5118. 2018.PubMed/NCBI
18	Baumann C, Bonilla WV, Fröhlich A, Helmstetter C, Peine M, Hegazy AN, Pinschewer DD and Löhning M: T-bet- and STAT4-dependent IL-33 receptor expression directly promotes antiviral Th1 cell responses. Proc Natl Acad Sci USA. 112:4056–4061. 2015. View Article : Google Scholar : PubMed/NCBI
19	Koch MA, Thomas KR, Perdue NR, Smigiel KS, Srivastava S and Campbell DJ: T-bet(+) Treg cells undergo abortive Th1 cell differentiation due to impaired expression of IL-12 receptor β2. Immunity. 37:501–510. 2012. View Article : Google Scholar : PubMed/NCBI
20	Akira S, Nishio Y, Inoue M, Wang XJ, Wei S, Matsusaka T, Yoshida K, Sudo T, Naruto M and Kishimoto T: Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathway. Cell. 77:63–71. 1994. View Article : Google Scholar : PubMed/NCBI
21	Jiang LH, Hao YL and Zhu JW: Expression and prognostic value of HER-2/neu, STAT3 and SOCS3 in hepatocellular carcinoma. Clin Res Hepatol Gastroenterol. 43:282–291. 2019. View Article : Google Scholar
22	Fathi N, Rashidi G, Khodadadi A, Shahi S and Sharifi S: STAT3 and apoptosis challenges in cancer. Int J Biol Macromol. 117:993–1001. 2018. View Article : Google Scholar : PubMed/NCBI
23	Chu Y, Wang Y, Peng W, Xu L, Liu M, Li J, Hu X, Li Y, Zuo J and Ye Y: STAT3 activation by IL-6 from adipose-derived stem cells promotes endometrial carcinoma proliferation and metastasis. Biochem Biophys Res Commun. 500:626–631. 2018. View Article : Google Scholar : PubMed/NCBI
24	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar
25	Raju S, Joseph R and Sehgal S: Review of checkpoint immunotherapy for the management of non-small cell lung cancer. Immunotargets Ther. 7:63–75. 2018. View Article : Google Scholar : PubMed/NCBI
26	Sabharwal SS, Waypa GB, Marks JD and Schumacker PT: Peroxiredoxin-5 targeted to the mitochondrial intermembrane space attenuates hypoxia-induced reactive oxygen species signal-ling. Biochem J. 456:337–346. 2013. View Article : Google Scholar : PubMed/NCBI
27	Pan Y, Liu G, Zhou F, Su B and Li Y: DNA methylation profiles in cancer diagnosis and therapeutics. Clin Exp Med. 18:1–14. 2018. View Article : Google Scholar
28	Zhang HH, Hu J, Zhou YL, Qin X, Song ZY, Yang PP, Hu S, Jiang X and Xu GY: Promoted interaction of nuclear factor-kB with demethylated purinergic P2X3 receptor gene contributes to neuropathic pain in rats with diabetes. Diabetes. 64:4272–4284. 2015. View Article : Google Scholar : PubMed/NCBI
29	Zhou YL, Jiang GQ, Wei J, Zhang HH, Chen W, Zhu H, Hu S, Jiang X and Xu GY: Enhanced binding capability of nuclear factor-kB with demethylated P2X3 receptor gene contributes to cancer pain in rats. Pain. 156:1892–1905. 2015. View Article : Google Scholar : PubMed/NCBI
30	Choi HI, Ma SK, Bae EH, Lee JU and Kim SW: Peroxiredoxin 5 protects TGF-β induced fibrosis by inhibiting stat3 activation in rat kidney interstitial fibroblast cells. PLoS One. 11:e01492662016. View Article : Google Scholar
31	Chen T, You Y, Jiang H and Wang ZZ: Epithelial-mesenchymal transition (EMT): A biological process in the development, stem cell differentiation, and tumorigenesis. J Cell Physiol. 232:3261–3272. 2017. View Article : Google Scholar : PubMed/NCBI
32	Acloque H, Ocaña OH, Matheu A, Rizzoti K, Wise C, Lovell-Badge R and Nieto MA: Reciprocal repression between Sox3 and snail transcription factors defines embryonic territories at gastrulation. Dev Cell. 21:546–558. 2011. View Article : Google Scholar : PubMed/NCBI
33	Correa-Costa M, Andrade-Oliveira V, Braga TT, Castoldi A, Aguiar CF, Origassa CST, Rodas ACD, Hiyane MI, Malheiros DMAC, Rios FJO, et al: Activation of platelet- activating factor receptor exacerbates renal inflammation and promotes fibrosis. Lab Invest. 94:455–466. 2014. View Article : Google Scholar : PubMed/NCBI
34	Ruscetti M, Quach B, Dadashian EL, Mulholland DJ and Wu H: Tracking and functional characterization of epithelial-mesen-chymal transition and mesenchymal tumor cells during prostate cancer metastasis. Cancer Res. 75:2749–2759. 2015. View Article : Google Scholar : PubMed/NCBI
35	Grande MT, Sanchez-Laorden B, Lopez-Blau C, De Frutos CA, Boutet A, Arévalo M, Rowe RG, Weiss SJ, López-Novoa JM and Nieto MA: Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat Med. 21:989–997. 2015. View Article : Google Scholar : PubMed/NCBI
36	Ahn HM, Yoo JW, Lee S, Lee HJ, Lee HS and Lee DS: Peroxiredoxin 5 promotes the epithelial-mesenchymal transition in colon cancer. Biochem Biophys Res Commun. 487:580–586. 2017. View Article : Google Scholar : PubMed/NCBI
37	Stewart D, Killeen E, Naquin R, Alam S and Alam J: Degradation of transcription factor Nrf2 via the ubiquitin-proteasome pathway and stabilization by cadmium. J Biol Chem. 278:2396–2402. 2003. View Article : Google Scholar
38	Nguyen T, Sherratt PJ, Huang HC, Yang CS and Pickett CB: Increased protein stability as a mechanism that enhances Nrf2-mediated transcriptional activation of the antioxidant response element. Degradation of Nrf2 by the 26 S proteasome. J Biol Chem. 278:4536–4541. 2003. View Article : Google Scholar